Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1365-1377

  Borah, Bijan J ^a   Huang, Xingyue ^b   Zarotsky, Victoria ^a,c   Globe, Denise ^b  

^a i3 Innovus   (United States)

^b AMGEN INC   (United States)

^c NONE   (United States)

Author keywords

Adalimumab; Cost; Etanercept; Medication adherence; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT;

ADULT; ARTICLE; COST OF ILLNESS; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; IMMUNOGLOBULIN G; INFANT; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 67649424376     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902896386     Document Type: Article

References (37)

1. Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-1289 (Pubitemid 20152491)
2. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev 1981;3:27-44 (Pubitemid 12164153)
3. Allaire SL, Prashker M, Meenan R. The costs of rheumatoid arthritis. Pharmacoeconomics 1994;6:513-522
4. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33 (Pubitemid 30095403)
5. Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23:59-69
6. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007;45:S66-76
7. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006;8:R174
8. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53 (Pubitemid 44476656)
9. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Arthritis Investigators Group. Arch Intern Med 1999;159:2542-2550
10. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-1602
11. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-1593 (Pubitemid 32162981)
12. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45 (Pubitemid 36091645)
13. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-346
14. van den Bemt BJ, van Lankveld WG. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol 2007;3:681
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497 (Pubitemid 41127293)
16. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574 (Pubitemid 44336271)
17. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum 2009;38:396-402
18. Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/ Downloads/HIPAALaw.pdf [Last accessed 26 August 2008]
19. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. Comorbidity Software. Available at: http://www.hcupus.ahrq. gov/toolssoftware/comorbidity/comorbidity.jsp [Last accessed 26 August 2008]
20. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12 (Pubitemid 46161090)
21. Rizzo JA, Simmons R. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997;19:1446-1457 (Pubitemid 28133280)
22. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003;9:S136-43 (Pubitemid 37345201)
23. Rosenbaum P, Rubin DB. The central role of the propensity score matching in observational studies for causal effects. Biometrika 1983;70:41-55
24. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat 2002;84:151-161
25. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporates the propensity score. American Statistician 1985;39:33-38
26. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-171 (Pubitemid 29052479)
27. Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Am Stat Assoc 2001;95:573-585
28. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-171 (Pubitemid 29052479)
29. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494
30. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman and Hall/CRC, 1993
31. StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp LP
32. Hughes DA, Bagust A, Haycox A, et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001;10:601-615 (Pubitemid 32998372)
33. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. Pharmacoeconomics 1999;15:217-228 (Pubitemid 29133459)
34. Brixner DI, Ho MJ. Clinical, humanistic, and economic outcomes of gout. Am J Manag Care 2005;11:S459-64
35. Galindo-Rodriguez G, Avina-Zubieta JA, Russell AS, et al. Disappointing long term results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999;26:2337-2343 (Pubitemid 29528968)
36. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-632
37. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs. Rheumatology (Oxford) 2000;39:975-8136